Eli Lilly (LLY)
(Delayed Data from NYSE)
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $886.00 -1.16 (-0.13%) 6:10 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $886.00 -1.16 (-0.13%) 6:10 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%
by Zacks Equity Research
Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $329.47, marking a +0.73% move from the previous day.
Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%
by Zacks Equity Research
Novo Nordisk (NVO) plans to lower prices of several pre-filled insulin pens and vials by up to 75% in the United States. However, the company plans not to start this until January 2024.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK
by Kinjel Shah
FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $316.85 in the latest trading session, marking a +1.38% move from the prior day.
Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study
by Zacks Equity Research
Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.
Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer
by Zacks Equity Research
Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.
Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study
by Zacks Equity Research
Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
by Zacks Equity Research
The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $318.43 in the latest trading session, marking a +1.07% move from the prior day.
NVS vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Analyst Blog Highlights Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences
by Zacks Equity Research
Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences are part of the Zacks top Analyst Blog.
Top Analyst Reports for Tesla, Eli Lilly & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Eli Lilly and Company (LLY) and Bank of America Corporation (BAC).
Pfizer (PFE) Eczema Drug Cibinqo Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approval for Pfizer's (PFE) Cibinqo to treat moderate-to-severe atopic dermatitis in adolescents was based on data from the phase III study, JADE TEEN.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
A Look at Pharma ETFs Post Q4 Earnings
by Sweta Killa
Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.